# VNDA earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VNDA) · [Earnings tab](https://www.lopjlb.com/stock/VNDA?tab=earnings) Updated: 2026-10-28T05:24:27 Quarters analyzed: 8 ## Cross-quarter narrative Across eight earnings calls from Q3 2024 to Q2 2026, Vanda’s story shifted from vague guidance to a clearer picture of growth and pressure. Fanapt emerged as the primary growth engine, with prescriptions rising 14‑32% YoY, new‑to‑brand starts surging, and commercial expansion milestones staying on track. By contrast, Hetlioz’s trajectory turned negative as generic competition drove volume declines of 24‑42% and created inventory‑related volatility. Ponvory’s performance weakened, slipping 18% and facing a $3 million variable‑consideration dispute. The pipeline showed steady progress: NEREUS received FDA approval and launched via a direct‑to‑consumer model, BYSANTI secured FDA approval, and multiple Phase‑III studies remained on schedule, though Imsidolimab and VQW‑765 entered at‑risk review phases. Cash burned down from $340.9 M to $170 M, prompting repeated mentions of runway sufficiency through 2027. Guidance has been largely maintained, but uncertainty persisted around regulatory reviews, reimbursement reforms, and market adoption. Overall, the company’s commercial upside is anchored by Fanapt and new launches, while generic erosion, regulatory delays, and cash consumption remain persistent headwinds. ## Latest CallCard · Q2 Vanda reports strong Fanapt growth, NEREUS launch, BYSANTI approval and expects operating expenses to moderate later in 2026, with cash sufficient through 2027. **Guidance:** maintained — Management reiterated expectation that operating expenses will begin decreasing by the end of 2026 and more substantially in 2027. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.2 Prepared remarks highlighted continued strong growth of Fanapt, enthusiastic response to NEREUS and upcoming BYSANTI launch, projecting expense moderation later in the year. ### Demand visibility Strong Fanapt demand and early NEREUS uptake; BYSANTI launch pending. Fanapt total prescriptions up 31% QoQ and new‑to‑brand 32%; NEREUS launched May 2026 with $1M sales and $15.2M inventory stocking, but $12.6M revenue constrained due to demand uncertainty. ### Margins / costs Operating expenses rose due to commercial and R&D spend, but are expected to moderate. First‑half operating expenses $216.3M, up $34.1M driven by SG&A for Fanapt, PONVORY, NEREUS, BYSANTI and higher R&D for phase‑3 programs; moderation anticipated later 2026/27. ### Capital allocation Cash of $170M deemed sufficient through 2027; investments focus on launch activities and R&D. Cash decreased $93.8M YoY; $10M milestone payment to Eli Lilly; salesforce of ~300 reps for Fanapt/BYSANTI and ~50 for PONVORY allocated to support NEREUS launch. ### Milestones - **Fanapt commercial expansion** [on_track]: TRx up 31% QoQ and NBRx up 32%, indicating strong momentum. - **NEREUS launch** [on_track]: Commercially available May 2026; $1M sales, $15.2M inventory stocked, constrained $12.6M pending demand. - **BYSANTI FDA approval** [delivered]: Approved Q1 2026, launch planned H2 2026. - **Imsidolimab BLA review** [at_risk]: Under FDA review with PDUFA target Dec 12 2026; orphan designations obtained. - **VQW‑765 phase 3** [at_risk]: Phase 3 ongoing, results expected 2026; powered based on phase 2 data. - **HETLIOZ generic competition** [delayed]: Revenue down 42% due to generic competition and shipment timing. - **VCA‑894A rare pediatric designation** [new]: FDA granted rare pediatric disease designation July 2026. - **HETLIOZ administrative hearing** [on_track]: 5‑day hearing scheduled Dec 2026, proceeding as planned. ### Fears / risks - **Regulatory risk**: Imsidolimab BLA under FDA review with a Dec 2026 PDUFA target; outcomes uncertain. - **Commercial demand uncertainty**: NEREUS constrained revenue reflects uncertainty around patient uptake and returns. - **Generic competition**: Hetlioz faces significant volume decline (42%) from generic competition. - **Litigation risk**: Company acknowledges ongoing litigation but declines to speculate on outcomes. - **Cash runway**: Cash fell to $170M, a $93.8M YoY decline, though management says resources suffice through 2027. ### Key quotes > “We are pleased with the continued strong growth of Fanapt and the enthusiastic response to NEREUS as it becomes available to patients.” ## Quarter one-liners - **2026 Q2:** Vanda reports strong Fanapt growth, NEREUS launch, BYSANTI approval and expects operating expenses to moderate later in 2026, with cash sufficient through 2027. - **2026 Q1:** Vanda posted modest revenue growth, strong Fanapt demand, launched NEREUS via a direct-to-consumer model, secured BYSANTI approval and raised full-year guidance, while noting generic pressure on HETLIOZ and cash burn. - **2025 Q4:** Vanda reports 2025 revenue up 9% to $216M driven by Fanapt growth; FDA approved Nereus for motion sickness; 2026 guidance $230-260M from current products; Vasanti PDUFA Feb 21; pipeline advancing across psychiatry and immunology. - **2025 Q3:** — - **2025 Q2:** Vanda sees strong Fanapt growth, reiterates 2025 revenue guidance, notes Bysanti launch timeline and $3M PONVORY dispute, while flagging HETLIOZ volatility and tradipitant hearing uncertainty. - **2025 Q1:** Fanapt sales surged 14% with prescriptions over 2,000 per week, while HETLIOZ held market share despite generics; PONVORY fell 18%, pipeline filings progressed and operating expenses rose, leaving cash at $340.9 M. - **2024 Q4:** Vanda reported modest revenue growth driven by Fanapt and Ponvory, noted Hetlioz decline from generics, outlined multiple pipeline submissions, and reaffirmed 2025 guidance that excludes Tradipitant and Imsidolimab contributions. - **2024 Q3:** — ## Theme arcs - **Fanapt commercial performance** (improving): Prescriptions up 14‑32% YoY, new‑to‑brand starts up >200%, consistent on‑track launch milestones. - **Hetlioz market position** (deteriorating): Generic competition caused 24‑42% YoY volume decline and inventory‑driven sales volatility. - **Ponvory uptake** (deteriorating): Revenue fell 18%, limited specialty prescriber capacity, $3 M dispute over variable consideration. - **Pipeline progress** (improving): NEREUS approved and launched, BYSANTI FDA‑approved, multiple Phase‑III studies on track; some assets (Imsidolimab, VQW‑765) at risk. - **Cash runway** (deteriorating): Cash fell from $340.9 M to $170 M, but management asserts sufficiency through 2027. - **Guidance consistency** (stable): Revenue guidance maintained in most quarters despite underlying volatility. - **Commercial expansion investment** (improving): Ongoing sales‑force expansion, DTC campaigns for NEREUS, and licensing activities. ## Guidance path 2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:raised → 2026 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/VNDA`